Innate Pharma (IPHA) Cash & Equivalents (2017 - 2025)

Innate Pharma (IPHA) has disclosed Cash & Equivalents for 6 consecutive years, with $76.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash & Equivalents changed N/A year-over-year to $76.0 million, compared with a TTM value of $76.0 million through Dec 2023, changed N/A, and an annual FY2023 reading of $76.4 million, changed N/A over the prior year.
  • Cash & Equivalents was $76.0 million for Q4 2023 at Innate Pharma, down from $118.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $224.6 million in Q4 2019 and bottomed at $76.0 million in Q4 2023.
  • Average Cash & Equivalents over 4 years is $145.6 million, with a median of $140.9 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents increased 29.18% in 2019, then decreased 27.38% in 2020.
  • Year by year, Cash & Equivalents stood at $224.6 million in 2019, then fell by 27.38% to $163.1 million in 2020, then dropped by 27.22% to $118.7 million in 2021, then plummeted by 36.0% to $76.0 million in 2023.
  • Business Quant data shows Cash & Equivalents for IPHA at $76.0 million in Q4 2023, $118.7 million in Q4 2021, and $163.1 million in Q4 2020.